News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
How the Wegovy Pill Approval Reshapes Solid Dosage Manufacturing Strategy
2
Strategies for Building Pharmaceutical Supply Chain Resilience in a Shifting Market
3
Harnessing Data and Secure Cloud Environments for Global Pharma Solutions
4
Integrated Digital Workflow Essential in 2026
5